Journal
FUTURE MEDICINAL CHEMISTRY
Volume 10, Issue 19, Pages 2253-2264Publisher
FUTURE SCI LTD
DOI: 10.4155/fmc-2018-0172
Keywords
acute lung injury; inflammatory diseases; lipopolysaccharide; macrophage; myricetin
Categories
Funding
- National Natural Science Foundation of China [81672297]
- National Key Research and Development Program 'Precision Medicine Research' from the Ministry of Science and Technology of China [2016YFC0903800]
Ask authors/readers for more resources
Aim: Acute lung injury is a common clinical syndrome associated with significant morbidity. Myricetin has been demonstrated to inhibit inflammation in a variety of diseases. In this study, we aimed to investigate the protective effects of myricetin on inflammation in lipopolysaccharide-stimulated RAW 264.7 cells and lipopolysaccharide-induced lung injury model. Results/methodology: In this study, we detected the anti-inflammatory effects of myricetin by ELISA, RT-PCR and Western blot, respectively. Myricetin significantly inhibited the production of the proinflammatory cytokines in vitro and in vivo. It exerted an anti-inflammatory effect through suppressing the NF-B p65 and AKT activation in NF-B pathway and JNK, p-ERK and p38 in MAPK signaling pathway. Conclusion: Myricetin alleviated acute lung injury by inhibiting macrophage activation, and inhibited inflammation in vitro and in vivo. It may be a potential therapeutic candidate for the prevention of inflammatory diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available